Visanne: First Endometriosis Treatment Subsidized by Australian Government in 30 Years
- Visanne, an endometriosis treatment, will be the first of its kind subsidised by the Australian federal government in 30 years.
- The medication, also known as dienogest, will have its price lowered from over $800 to $380 per year.
- Visanne releases a hormone that stops ovulation and menstruation.
Endometriosis Drug Visanne to Be Subsidised
Visanne, an endometriosis treatment, will be the first of its kind subsidised by the Australian federal government in 30 years. Health Minister Mark Butler will announce this development on Sunday morning.
Cost Reduction
The medication, also known as dienogest, will have its price lowered from over $800 to $380 per year. For pension and concession card holders, the cost will drop to about $90 annually.
How Visanne Works
Visanne releases a hormone that stops ovulation and menstruation. It helps reduce and control the growth of abnormal tissue linked to endometriosis. This chronic condition occurs when tissue similar to the womb lining grows in other parts of the body, often leading to severe pain and fertility issues.
Diagnosis Challenges
Endometriosis affects nearly 1 million Australians and results in around 40,000 hospital admissions each year. However, patients often wait more than six years for a proper diagnosis. This delay is primarily due to a lack of awareness among patients and healthcare professionals, who may misinterpret symptoms as normal period pain.
Announcement Details
Mr. Butler will reveal Visanne’s PBS listing at St Andrews Hospital in Adelaide, accompanied by medical experts and advocates for endometriosis.
Support from Advocacy Group
Syl Freedman, an endometriosis patient and co-founder of EndoActive, praised this decision. She highlighted the importance of affordable treatment options. Freedman noted that, despite growing awareness, significant knowledge gaps remain. She called for continued education and support to help women address this condition openly.